2000
DOI: 10.1016/s0304-4165(00)00005-2
|View full text |Cite
|
Sign up to set email alerts
|

Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
18
0

Year Published

2005
2005
2020
2020

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 44 publications
(18 citation statements)
references
References 20 publications
0
18
0
Order By: Relevance
“…The filamentous phage M13, which normally has E. coli as its host, was modified using phage display techniques to bind Helicobacter pylori [70]. Antigen-binding single chain variable fragments from murine hybridomas that produced monoclonal antibodies against H. pylori were expressed as a g3p fusion protein on the M13 phage.…”
Section: Alteration Of the Host Binding Profilementioning
confidence: 99%
“…The filamentous phage M13, which normally has E. coli as its host, was modified using phage display techniques to bind Helicobacter pylori [70]. Antigen-binding single chain variable fragments from murine hybridomas that produced monoclonal antibodies against H. pylori were expressed as a g3p fusion protein on the M13 phage.…”
Section: Alteration Of the Host Binding Profilementioning
confidence: 99%
“…They contain double-stranded or single-stranded DNA or RNA as the genome. Although most therapeutic phages are tailed, some cubic phages (fX174 and Qb) [35][36][37] or filamentous phages (M13 and Pf3) 38,39 have also been used (see later in this article).…”
Section: Classification Of Phagesmentioning
confidence: 99%
“…Furthermore, oral administration of the phage decreased the number of bacteria colonies in the stomachs of mice. 38 The release of endotoxin (lipopolysaccharide), a component of the outer membrane in gram-negative bacteria, by phage infection is thought to be an important problem in phage therapy. Recently, a unique method to minimize the release of endotoxin in phage therapy against P. aeruginosa disease was reported.…”
Section: But Merril Et Al Developed An Ingeniousmentioning
confidence: 99%
“…After this, many successful results using animal models were showed. The therapeutic efficacy of phage therapy against infectious diseases caused by Pseudomonas aeruginosa [149,150], Staphylococcus aureus (including methicillin-resistant S. aureus ) [151,152], E. coli [147], Enterococcus faecium (including vancomycin-resistant Enterococcus ) [153], Streptococcus pneumoniae [154], Helicobacter pylori [155], Klebsiella pneumoniae [156] and Salmonella enteritidis [157,158] has been shown in experimental animal models. With regards to human health, in the past, phage was administered in Poland and the Soviet Union orally, tropically or systemically to treat a wide variety of infections (suppurative wound, gastroenteritis, sepsis, osteomyelitis, dermatitis, emphysemas and pneumonia) in both adults and children [146].…”
Section: Phage Therapy: a Low Environmental Impact Technology As Amentioning
confidence: 99%